BACKGROUND: Mathematical models are commonly used to predict future benefits of new therapies or interventions in the healthcare setting. The reliability of model results is greatly dependent on accuracy of model inputs but on occasion, data sources may not provide all the required inputs. Therefore, calibration of model inputs to epidemiological endpoints informed by existing data can be a useful tool to ensure credibility of the results. OBJECTIVE: To compare different computational methods of calibrating a Markov model to US data. METHODS: We developed a Markov model that simulates the natural history of human papillomavirus (HPV) infection and subsequent cervical disease in the US. Because the model consists of numerous transition probabilities that cannot be directly estimated from data, calibration to multiple disease endpoints was required to ensure its predictive validity. Goodness of fit was measured as the mean percentage deviation of model-predicted endpoints from target estimates. During the calibration process we used the manual, random and Nelder-Mead calibration methods. RESULTS: The Nelder-Mead and manual calibration methods achieved the best fit, with mean deviations of 7% and 10%, respectively. Nelder-Mead accomplished this result with substantially less analyst time than the manual method, but required more intensive computing capability. The random search method achieved a mean deviation of 39%, which we considered unacceptable despite the ease of implementation of that method. CONCLUSIONS: The Nelder-Mead and manual techniques may be preferable calibration methods based on both performance and efficiency, provided that sufficient resources are available.
BACKGROUND: Mathematical models are commonly used to predict future benefits of new therapies or interventions in the healthcare setting. The reliability of model results is greatly dependent on accuracy of model inputs but on occasion, data sources may not provide all the required inputs. Therefore, calibration of model inputs to epidemiological endpoints informed by existing data can be a useful tool to ensure credibility of the results. OBJECTIVE: To compare different computational methods of calibrating a Markov model to US data. METHODS: We developed a Markov model that simulates the natural history of human papillomavirus (HPV) infection and subsequent cervical disease in the US. Because the model consists of numerous transition probabilities that cannot be directly estimated from data, calibration to multiple disease endpoints was required to ensure its predictive validity. Goodness of fit was measured as the mean percentage deviation of model-predicted endpoints from target estimates. During the calibration process we used the manual, random and Nelder-Mead calibration methods. RESULTS: The Nelder-Mead and manual calibration methods achieved the best fit, with mean deviations of 7% and 10%, respectively. Nelder-Mead accomplished this result with substantially less analyst time than the manual method, but required more intensive computing capability. The random search method achieved a mean deviation of 39%, which we considered unacceptable despite the ease of implementation of that method. CONCLUSIONS: The Nelder-Mead and manual techniques may be preferable calibration methods based on both performance and efficiency, provided that sufficient resources are available.
Authors: Milton C Weinstein; Bernie O'Brien; John Hornberger; Joseph Jackson; Magnus Johannesson; Chris McCabe; Bryan R Luce Journal: Value Health Date: 2003 Jan-Feb Impact factor: 5.725
Authors: N Muñoz; F X Bosch; S de Sanjosé; L Tafur; I Izarzugaza; M Gili; P Viladiu; C Navarro; C Martos; N Ascunce Journal: Int J Cancer Date: 1992-11-11 Impact factor: 7.396
Authors: M H Schiffman; H M Bauer; R N Hoover; A G Glass; D M Cadell; B B Rush; D R Scott; M E Sherman; R J Kurman; S Wacholder Journal: J Natl Cancer Inst Date: 1993-06-16 Impact factor: 13.506
Authors: Vicki B Benard; Christie R Eheman; Herschel W Lawson; Donald K Blackman; Christa Anderson; William Helsel; Sandra F Thames; Nancy C Lee Journal: Obstet Gynecol Date: 2004-03 Impact factor: 7.661
Authors: S K Kjaer; A J van den Brule; J E Bock; P A Poll; G Engholm; M E Sherman; J M Walboomers; C J Meijer Journal: Int J Cancer Date: 1996-03-01 Impact factor: 7.396
Authors: Jane J Kim; Karen M Kuntz; Natasha K Stout; Salaheddin Mahmud; Luisa L Villa; Eduardo L Franco; Sue J Goldie Journal: Am J Epidemiol Date: 2007-05-25 Impact factor: 4.897
Authors: M Kohli; N Ferko; A Martin; E L Franco; D Jenkins; S Gallivan; C Sherlaw-Johnson; M Drummond Journal: Br J Cancer Date: 2006-12-05 Impact factor: 7.640
Authors: Douglas C A Taylor; Vivek Pawar; Denise T Kruzikas; Kristen E Gilmore; Myrlene Sanon; Milton C Weinstein Journal: Pharmacoeconomics Date: 2012-02-01 Impact factor: 4.981
Authors: Linwei Wang; Emanuel Krebs; Jeong E Min; W Christopher Mathews; Ank Nijhawan; Charurut Somboonwit; Judith A Aberg; Richard D Moore; Kelly A Gebo; Bohdan Nosyk Journal: Lancet HIV Date: 2019-07-11 Impact factor: 12.767
Authors: Xiao Zang; Emanuel Krebs; Jeong E Min; Ankur Pandya; Brandon D L Marshall; Bruce R Schackman; Czarina N Behrends; Daniel J Feaster; Bohdan Nosyk Journal: Med Decis Making Date: 2019-12-22 Impact factor: 2.583
Authors: Bernhard Ultsch; Oliver Damm; Philippe Beutels; Joke Bilcke; Bernd Brüggenjürgen; Andreas Gerber-Grote; Wolfgang Greiner; Germaine Hanquet; Raymond Hutubessy; Mark Jit; Mirjam Knol; Rüdiger von Kries; Alexander Kuhlmann; Daniel Levy-Bruhl; Matthias Perleth; Maarten Postma; Heini Salo; Uwe Siebert; Jürgen Wasem; Ole Wichmann Journal: Pharmacoeconomics Date: 2016-03 Impact factor: 4.981
Authors: Warner K Huh; Erin Williams; Joice Huang; Tommy Bramley; Nick Poulios Journal: Appl Health Econ Health Policy Date: 2015-02 Impact factor: 2.561